A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Phase 1 Terminated 77 enrolled Pfizer

RandomizedParallel-groupDouble-blindBasic science

Summary

This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.

Timeline

Start: 2015-01-19
Primary completion: 2016-06-14
Completion: 2016-06-14

Outcome

Outcome not reported

Stopped (Enrollment): “Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study was not terminated for reasons of safety.”

Publications

Balice-Gordon R, Honey GD, Chatham C, Arce E, Duvvuri S, Naylor MG, Liu W, Xie Z, DeMartinis N, Harel BT, Braley GH, Kozak R, Park L, Gray DL. A Neurofunctional Domains Approach to Evaluate D1/D5 Dopamine Receptor Partial Agonism on Cognition and Motivation in Healthy Volunteers With Low Working Memory Capacity. Int J Neuropsychopharmacol. 2020 May 27;23(5):287-299. doi: 10.1093/ijnp/pyaa007.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-06412562	Unknown	3 mg	—
Subject	PF-06412562	Unknown	15 mg	—

Indications

No indication recorded.